1-(naphthalen-1-yl)but-2-en-1-one | 128113-46-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-(naphthalen-1-yl)but-2-en-1-one
• 英文别名: 1-[1]naphthyl-but-2-en-1-one；1-α-Naphthyl-buten-(2)-on-(1)；Propenyl-α-naphthyl-keton；1-[1]Naphthyl-but-2-en-1-on；1-Crotonoyl-naphthalin；5-Methylacryloylnaphthalene；1-naphthalen-1-ylbut-2-en-1-one
• CAS: 128113-46-2
• 化学式: C₁₄H₁₂O
• 分子量: 196.249
• InChiKey: FEDLUXBEDAPEAU-UHFFFAOYSA-N

物化性质

• 沸点：
  336.5±15.0 °C(Predicted)
• 密度：
  1.079±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(naphthalen-1-yl)but-2-en-1-one 在 氯仿 、 溴 作用下， 生成 2,3-dibromo-1-[1]naphthyl-butan-1-one
  参考文献：
  名称：

  Mayer; Mueller, Chemische Berichte, 1927, vol. 60, p. 2281

  摘要：

  DOI：
• 作为产物：
  描述：

  萘 在 二硫化碳 、 三氯化铝 作用下， 生成 1-(naphthalen-1-yl)but-2-en-1-one
  参考文献：
  名称：

  Mayer; Mueller, Chemische Berichte, 1927, vol. 60, p. 2281

  摘要：

  DOI：

文献信息

• PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME
  申请人：Mikoshiba Katsuhiko

  公开号：US20120277423A1

  公开（公告）日：2012-11-01

  The present invention relates to: a ketone compound having transglutaminase-inhibiting activity, which is represented by the following Formula 1, 2, or 3: wherein R 1 is a substituted or unsubstituted aryl or heterocyclyl group, R 2 , R 3 , and R 4 are hydrogen atoms, n is 2, X is halogen, R 5 and R 6 independently represent a hydrogen atom or a substituted or unsubstituted C1-C10 alkyl, aryl, or aralkyl group, wherein R 5 and R 6 are not hydrogen atoms at the same time, or R 5 and R 6 may be taken together to form a saturated or unsaturated and substituted or unsubstituted heterocyclyl group containing a nitrogen atom (N); an inhibitor of protein crosslinking comprising the compound; and a composition for preventing or treating a protein-crosslinking causative disease, which comprises the compound or the protein crosslinking inhibitor.

  本发明涉及：一种具有转谷氨酰胺酶抑制活性的酮化合物，由下式1、2或3表示： 其中R1是取代或未取代的芳基或杂环基团，R2、R3和R4是氢原子，n是2，X是卤素，R5和R6独立地表示氢原子或取代或未取代的C1-C10烷基、芳基或芳烷基团，其中R5和R6不同时为氢原子，或者R5和R6可以共同形成含氮原子（N）的饱和或未饱和的、取代或未取代的杂环基团；包含该化合物的蛋白质交联抑制剂；以及包含该化合物或蛋白质交联抑制剂的用于预防或治疗由蛋白质交联引起的疾病的组合物。
• NOVEL 5-HT2 ANTAGONISTS
  申请人：AnaMar AB

  公开号：EP3109237A1

  公开（公告）日：2016-12-28

  The present invention relates to 1-amidino-3-aryl-2-pyrazoline derivatives of the general formula I The invention specifically relates to such derivatives which exhibit antagonizing activity towards serotonin 5-HT2B receptors. The present invention also relates to use of said compounds as a medicament and for the treatment of fibrosis, cardiovascular diseases, pain, IBD, and other inflammatory diseases, as well as pharmaceutical compositions comprising one or more of said compounds and methods of treatment.

  本发明涉及通式I的1-酰胺基-3-芳基-2-吡唑啉衍生物。该发明具体涉及表现出对5-HT2B受体具有拮抗活性的这类衍生物。本发明还涉及将所述化合物用作药物以及用于治疗纤维化、心血管疾病、疼痛、炎症性肠病和其他炎症性疾病的用途，以及包含一种或多种所述化合物的药物组合物和治疗方法。
• [EN] NOVEL 5-HT2 ANTAGONISTS<br/>[FR] NOUVEAUX ANTAGONISTES 5-HT2
  申请人：ANAMAR AB

  公开号：WO2016207231A1

  公开（公告）日：2016-12-29

  The present invention relates to 1-amidino-3-aryl-2-pyrazoline derivatives of the general formula I The invention specifically relates to such derivatives which exhibit antagonizing activity towards serotonin 5-HT2B receptors. The present invention also relates to use of said compounds as a medicament and for the treatment of fibrosis, cardiovascular diseases, pain, IBD, and other inflammatory diseases, as well as pharmaceutical compositions comprising one or more of said compounds and methods of treatment.

  本发明涉及通式I的1-酰胺基-3-芳基-2-吡唑啉衍生物。本发明特别涉及具有拮抗5-羟色胺5-HT2B受体活性的这些衍生物。本发明还涉及使用所述化合物作为药物并用于治疗纤维化、心血管疾病、疼痛、炎症性肠病和其他炎症性疾病，以及包含一种或多种所述化合物的制药组合物和治疗方法。
• Inhibitor of protein crosslinking and use of the same
  申请人：Mikoshiba Katsuhiko

  公开号：US08937091B2

  公开（公告）日：2015-01-20

  The present invention relates to: a ketone compound having transglutaminase-inhibiting activity, which is represented by the following Formula 1, 2, or 3: wherein R1 is a substituted or unsubstituted aryl or heterocyclyl group, R2, R3, and R4 are hydrogen atoms, n is 2, X is halogen, R5 and R6 independently represent a hydrogen atom or a substituted or unsubstituted C1-C10 alkyl, aryl, or aralkyl group, wherein R5 and R6 are not hydrogen atoms at the same time, or R5 and R6 may be taken together to form a saturated or unsaturated and substituted or unsubstituted heterocyclyl group containing a nitrogen atom (N); an inhibitor of protein crosslinking comprising the compound; and a composition for preventing or treating a protein-crosslinking causative disease, which comprises the compound or the protein crosslinking inhibitor.

  本发明涉及具有转麦芽胺酰胺酶抑制活性的酮类化合物，其由以下式子1、2或3表示：其中R1是取代或未取代的芳基或杂环基，R2、R3和R4是氢原子，n为2，X为卤素，R5和R6分别表示氢原子或取代或未取代的C1-C10烷基、芳基或芳基烷基，其中R5和R6不能同时为氢原子，或R5和R6可以结合形成含有氮原子（N）的饱和或不饱和、取代或未取代的杂环基；一种蛋白交联抑制剂，包括该化合物；以及一种用于预防或治疗蛋白交联病因性疾病的组合物，其包括该化合物或蛋白交联抑制剂。
• Magnesium-Promoted Reductive Carboxylation of Aryl Vinyl Ketones: Synthesis of γ-Keto Carboxylic Acids
  作者：Suhua Zheng、Tianyuan Zhang、Hirofumi Maekawa

  DOI：10.1021/acs.joc.2c00557

  日期：2022.6.3

  Direct reductive carboxylation of easily prepared aryl vinyl ketones under the atmosphere of carbon dioxide led to the selective formation of γ-keto carboxylic acids in 38–86% yields. The reaction is characterized by the carbon–carbon bond formation of carbon dioxide at the β-position of enone, with the use of magnesium turnings that can be easily handled as the reducing agent and the eco-friendly

  容易制备的芳基乙烯基酮在二氧化碳气氛下的直接还原羧化导致以 38-86% 的产率选择性形成 γ-酮基羧酸。该反应的特点是二氧化碳在烯酮的β位形成碳-碳键，使用易于处理的镁屑作为还原剂，以及无加压、无压力等环保反应条件。反应温度低或高，反应时间短。该协议显示了广泛的底物范围，并提供了一种有用且方便的替代方法来获取生物学上重要的 γ-酮羧酸。